Rock Creek Pharmaceuticals, Inc. (RCPIQ) は上場企業です ヘルスケア セクターの バイオテクノロジー 業界で事業展開. 本社所在地は Sarasota, FL, アメリカ. 現CEOは Michael John Mullan MBBS (M.D.,),.
RCPIQ を有する IPO日 1998-02-27, 5 名の正社員, に上場 Other OTC.
Rock Creek Pharmaceuticals, Inc., a pharmaceutical development company, focuses on the discovery, development, and commercialization of therapies for chronic inflammatory disease and neurologic disorders. Its lead compound is Anatabine citrate, a small molecule, cholinergic agonist, which exhibits anti-inflammatory pharmacological characteristics, with a mechanism of action distinct from other anti-inflammatory drugs available, such as biologics, steroids, and non-steroidal anti-inflammatories. The company was formerly known as Star Scientific, Inc. and changed its name to Rock Creek Pharmaceuticals, Inc. in June 2014. Rock Creek Pharmaceuticals, Inc. is headquartered in Sarasota, Florida. On September 27, 2016, Rock Creek Pharmaceuticals, Inc., along with its affiliates, filed a voluntary petition for liquidation under Chapter 7 in the US Bankruptcy Court for the District of Delaware.
